Autoimmune polyendocrine syndrome primary prevention

Autoimmune polyendocrine syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Autoimmune polyendocrine syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Autoimmune polyendocrine syndrome primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Autoimmune polyendocrine syndrome primary prevention
CDC on Autoimmune polyendocrine syndrome primary prevention
Autoimmune polyendocrine syndrome primary prevention in the news
Blogs on Autoimmune polyendocrine syndrome primary prevention
Directions to Hospitals Treating Autoimmune polyendocrine syndrome
Risk calculators and risk factors for Autoimmune polyendocrine syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Primary Prevention

• There are no established measures for the primary prevention of [disease name].
• There are no available vaccines against [disease name].

OR

• Effective measures for the primary prevention of autoimmune polyendocrine syndrome (APS) include:
  • Patient education: Autoimmune polyendocrine syndrome may be inherited in autosomal recessive (APS type 1), autosomal dominant (APS type 2) or X linked fashion (APS type 3) and therefore educating relatives about presence of APS in family is necessary.
  • Screening should be done for first degree relatives of patients with APS for auto-antibodies against 21- hydroxylase, 17-hydroxylase, thyroid peroxidase, parietal cell, anti-intrinsic factor and islet cell antibodies.
  • Currently, there is not enough evidence to define optimal intervals for testing but data suggests that autoantibodies can develop at any age. Hence, we rescreen patients for autoantibodies even if their initial autoantibody tests are negative. Celiac disease, for instance, is usually asymptomatic and only detected after screening for transglutaminase autoantibodies.